ToleroMune® Cat Allergy Treatment Clinical Results - Rapid Four-Dose Regimen Maintains Significant Symptom Reduction One Year After Starting

Date: Oct-01-2012Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today
announced the publication of positive phase II results with its ToleroMune(R) cat allergy
treatment in the Journal of Allergy and Clinical Immunology (JACI). The results show that
cat allergy patients who received four doses of ToleroMune(R) treatment over 12 weeks
maintained a significantly greater improvement in symptoms one year after the start of the
study compared with placebo (p=0.0104).

"These results are extremely encouraging, as they suggest our novel ToleroMune(R) cat
allergy therapy has the potential to modify the underlying allergic disease, and thereby
offer patients ongoing symptom improvement after just a short course of treatment," said
Steve Harris, Circassia's CEO. "The peer-reviewed publication of these clinical results in
the leading journal in the allergy field, the Journal of Allergy and Clinical Immunology,
is an important achievement for Circassia as we rapidly progress our ToleroMune(R)
treatment into phase III development."

The study, 'Fel d 1-derived peptide antigen desensitization shows a persistent
treatment effect 1 year after the start of dosing: A randomized, placebo-controlled
study,' was published online on 17 September*, and will appear in an upcoming edition of
JACI. The trial included 202 patients with cat allergy who received placebo or Circassia's
ToleroMune(R) treatment, which consists of seven synthetic peptides derived from the major
cat allergen Fel d 1. One year after the start of the study, 89 patients returned to
reassess their symptoms while exposed to cat allergens. The study found an immediate and
continuing improvement in patients' symptoms following four doses of the ToleroMune(R)
treatment over 12 weeks, and a significant decrease compared with placebo one year after
the start of the trial despite no further dosing. The authors note that the symptom
reduction represents a substantial improvement over a number of allergy treatment
approaches investigated previously. The ToleroMune(R) treatment was well tolerated and had
a safety profile similar to placebo.

Courtesy: Medical News Today Note: Any medical information available in this news section is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional.